A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients-Reference-Cited by-同舟云学术

A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients

Published:2020-04 Issue: Volume:50 Page:30-38
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Yeo Winnie^ORCID,Lau Thomas KH.,Li Leung,Lai Kwai Tung,Pang Elizabeth,Cheung Maggie,Chan Vicky TC.,Wong Ashley,Soo Winnie MT.,Yeung Vanessa TY.,Tse Teresa,Lam Daisy CM.,Yeung Eva WM.,Ng Kim PK.,Tang Nelson LS.,Tong Macy,Suen Joyce JS.,Mo Frankie KF.

Funder

Madam Diana Hon Fun Kong Donation for Cancer Research

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference30 articles.

1. State of the art antiemetic therapy for cancer patients;Lau;Curr Oncol Rep,2016

2. Prevention of delayed nausea: a university of Rochester Cancer center community clinical oncology program study of patients receiving chemotherapy;Roscoe;J Clin Oncol,2012

3. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993;Griffin;Ann Oncol,1996

4. Antiemetics: American society of clinical oncology focused guideline update;Hesketh;J Clin Oncol,2016

5. Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy;Herrstedt;Support Care Cancer,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26

2. Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials;Cancer Management and Research;2024-04

3. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting;ESMO Open;2024-02

4. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents;Supportive Care in Cancer;2023-12-21

5. Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial);British Journal of Cancer;2023-11-16